Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

REDWOOD CITY, Calif., Dec. 9 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery. The primary endpoint evaluated pain intensity (Sum of the Pain Intensity Difference - SPID12) over the 12-hour study period compared to baseline. Results demonstrated that compared to placebo, patients receiving 15 mcg of ARX-01 experienced a statistically significant reduction in pain intensity over the study period, based on the worst observation carried forward imputation method (WOCF), p=0.015. Additionally, at the 15 mcg dose, the study met an important secondary endpoint compared to placebo, the percentage of patient dropouts due to inadequate analgesia, p=0.006. Further, no serious or unexpected adverse events related to ARX-01 were reported in the study.

ARX-01 is a sublingual formulation of the opioid pain medication, sufentanil. ARX-01 is based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.

"We chose a very painful surgery in an elderly patient population to showcase the efficacy and safety of Sublingual Sufentanil NanoTabs in treating acute post-operative pain," said Pamela Palmer, M.D., Ph.D., chief medical officer of AcelRx Pharmaceuticals. "The superior attributes of both the drug and the dosage form enabled these highly encouraging Phase 2 results."

This multicenter, double-blind, randomized, placebo-controlled, dose-finding Phase 2 study evaluated the safety and efficacy of ARX-01 in patients undergoing elective unilateral knee replacement surgery. In the study, 101 patients were randomized to receive either placebo or one of three different dosage strengths of ARX-01: 5mcg, 10m
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Mass. , July 1, 2015   ... most frequently cited advantages of Otezla are its ... safety profile, as reported by surveyed rheumatologists. Otezla ... launched for the treatment of active psoriatic arthritis ... The current standard of care includes conventional oral ...
(Date:7/1/2015)... -- Isagenix International, a leading global health and wellness ... and three Bronze Stevie® Awards at the 2015 Annual ... this month.The American Business Awards ... the U.S. "Winning is a tremendous ... cultivating talent, creating a unified team, and crafting the ...
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
(Date:6/30/2015)... 2015  NASA astronaut Kjell Lindgren , who is ... first mission to the International Space Station , will ... a.m. EDT Tuesday, July 7. Lindgren will participate ... Russia . The interviews will be preceded at ... mission training. To schedule an interview, media must ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2
... Chemotherapy-Induced Nausea and Vomiting, According to a New Report from ... ... 2008 Decision Resources, one,of the world,s leading research and advisory ... Emend for,Injection/Ivemend combined with 5-HT3 RA, is positioned to earn,gold-standard status ...
... DIEGO, April 9, 2008 ADVENTRX,Pharmaceuticals, Inc. (Amex: ... appointed,Jose Hechavarria to the new position of vice ... leading the company,s planned,commercial manufacturing operations., "We ... team," said Evan M.,Levine, ADVENTRX chief executive officer. ...
... by Johns Hopkins researchers has solved important puzzles concerning ... that could lead to a new type of antibiotics. ... Current Biology, the scientists reported how a belt-like structure ... to produce two offspring, can be disabled by a ...
Cached Biology Technology:New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting 2New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting 3ADVENTRX Appoints Vice President of Manufacturing 2ADVENTRX Appoints Vice President of Manufacturing 3Solving the Z ring's mysteries may lead to new antibiotics 2Solving the Z ring's mysteries may lead to new antibiotics 3
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/24/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Huawei ... Analysis" report to their offering. ... going to the opposite direction than Apple,s and ... innovative fingerprint sensor developed by Fingerprint Cards, a ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... with Alzheimer's disease in the brain of the fruit ... death and proteins previously associated with cancer. , The ... colleagues from Brigham and Women's Hospital, Harvard Medical School, ... generally do not divide. It is therefore perplexing that ...
... engineered mice whose hearts glow with a green light ... into how hearts develop in living mouse embryos and ... arrhythmias, as well as open doors to observing cellular ... The technique for making living, functional cells fluoresce, or ...
... researchers have been able to show that a natural ... can also do so in at least one vertebrate ... Scuola Normale Superiore, Pisa, and colleagues, support the potential ... The development of drugs able to retard the onset ...
Cached Biology News:Mice with glowing hearts shed light on how hearts develop 2Resveratrol prolongs lifespan and delays onset of aging-related traits in a short-lived vertebrate 2
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... Formula variant: With the macro- ... Murashige and Skoog (1962) and ... Gamborg, et al. (1968). Preparation ... 4.4 grams of powder per ...
... CBED Maxi Kit provides a fast and ... protein solutions for buffer exchange, and for removing ... kit is based on spin-column chromatography using Norgens ... such as MgCl 2 , NaCl, KCl, CaCl ...
... The new Finnigan Pocket Surveyor ... new and existing Finnigan Surveyor HPLC ... handheld computer running the popular Windows ... chromatographers the ability to connect directly ...
Biology Products: